Cargando…
Clinical and Translational Advances in Glioma Immunotherapy
Gliomas are highly treatment refractory against immune checkpoint blockade, an immunotherapeutic modality that revolutionized therapy for many tumors. At the same time, technological innovation has dramatically accelerated the development of immunotherapeutic approaches such as personalized tumor-sp...
Autores principales: | Bunse, Lukas, Bunse, Theresa, Krämer, Christopher, Chih, Yu-Chan, Platten, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723056/ https://www.ncbi.nlm.nih.gov/pubmed/36303101 http://dx.doi.org/10.1007/s13311-022-01313-9 |
Ejemplares similares
-
Genetically Modified Cellular Therapies for Malignant Gliomas
por: Kilian, Michael, et al.
Publicado: (2021) -
Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
por: Elmadany, Nirmeen, et al.
Publicado: (2022) -
K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017) -
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
por: Friedrich, Mirco, et al.
Publicado: (2022) -
Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)